Novo-Nordisk seeks injunction to block launch of Sanofi-Aventis insulin pen

Share this article:

Novo Nordisk has filed legal action in the US to block the launch of Sanofi-Aventis' new Solo-Star insulin injection pen, The Financial Times reports.

Novo Nordisk is seeking an injunction because it claims Sanofi’s Solo-Star pen infringes on the patents on its NovoPen 4.

Sanofi-Aventis’ Solo-Star injection pen, which administers Lantus insulin, was recently approved by the FDA. Sanofi-Aventis launched Solo-Star in France and Germany in May and has plans to introduce it elsewhere across Europe and in the US in the months ahead.

Both insulin pens will be competing in a global insulin market worth up to $8.2 billion.

Sanofi-Aventis said in the Financial Times report that it disagreed with Novo Nordisk’s claims and would “vigorously defend” its rights.

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.